Iodine mediated mechanisms and thyroid carcinoma

References

• Bizhanova A, Kopp P. The sodium-iodide symporter NIS and pendrin in iodide homeostasis of the thyroid. Endocrinology 2009;150: 1084–1090.
   PubMed Web of Science ®Google Scholar
• Dohan O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, Ginter CS, Carrasco N. The sodium/iodide symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 2003; 24: 48–77.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71–96.
   PubMed Web of Science ®Google Scholar
• Neff RL, Farrar WB, Kloos RT, Burman KD. Anaplastic thyroid cancer. Endocrinol Metab Clin North Am 2008; 37: 525–538.
   PubMed Web of Science ®Google Scholar
• Toniato A, Boschin I, Casara D, Mazzarotto R, Rubello D, Pelizzo M. Papillary thyroid carcinoma: factors influencing recurrence and survival. Ann Surg Oncol 2008; 15: 1518–1522.
   PubMed Web of Science ®Google Scholar
• Maier J, van Steeg H, van Oostrom C, Paschke R, Weiss RE, Krohn K. Iodine deficiency activates antioxidant genes and causes DNA damage in the thyroid gland of rats and mice. Biochim Biophys Acta 2007; 1773: 990–999.
   PubMed Web of Science ®Google Scholar
• Krohn K, Maier J, Paschke R. Mechanisms of disease: hydrogen peroxide, DNA damage and mutagenesis in the development of thyroid tumors. Nat Clin Pract Endocrinol Metab 2007; 3: 713–720.
   PubMedGoogle Scholar
• Dal Maso L, Bosetti C, La Vecchia C, Franceschi S. Risk factors for thyroid cancer: an epidemiological review focused on nutritional factors. Cancer Causes Control 2009; 20: 75–86.
   PubMed Web of Science ®Google Scholar
• Dijkstra B, Prichard RS, Lee A, Kelly LM, Smyth PP, Crotty T, McDermott EW, Hill AD, O’Higgins N. Changing patterns of thyroid carcinoma. Ir J Med Sci 2007; 176: 87–90.
   Google Scholar
• Farahati J, Geling M, Mader U, Mortl M, Luster M, Muller JG, Flentje M, Reiners C. Changing trends of incidence and prognosis of thyroid carcinoma in lower Franconia, Germany, from 1981-1995. Thyroid 2004; 14: 141–147.
   PubMed Web of Science ®Google Scholar
• Vitale M, Di Matola T, D’Ascoli F, Salzano S, Bogazzi F, Fenzi G, Martino E, Rossi G. Iodide excess induces apoptosis in thyroid cells through a p53-independent mechanism involving oxidative stress. Endocrinology 2000; 141: 598–605.
   PubMed Web of Science ®Google Scholar
• Gimm O. Thyroid cancer. Cancer Lett 2001; 163: 143–156.
   PubMed Web of Science ®Google Scholar
• Kuo SF, Chao TC, Chang HY, Hsueh C, Chang YC, Yang CH, Lin JD. The role of radioactive iodine therapy in young patients with papillary thyroid cancer. Clin Nucl Med 2009; 34: 4–6.
   Google Scholar
• Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 2005; 103: 1330–1335.
   PubMed Web of Science ®Google Scholar
• Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 2009; 16: 17–44.
   PubMed Web of Science ®Google Scholar
• Hunt JL, Tometsko M, LiVolsi VA, Swalsky P, Finkelstein SD, Barnes EL. Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas of the thyroid. Am J Surg Pathol 2003; 27: 1559–1564.
   PubMedGoogle Scholar
• Nikiforov YE. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr Pathol 2004; 15: 319–327.
   PubMed Web of Science ®Google Scholar
• Kloos RT. Papillary thyroid cancer: medical management and follow-up. Curr Treat Options Oncol 2005; 6: 323–338.
   Google Scholar
• Chiacchio S, Lorenzoni A, Boni G, Rubello D, Elisei R, Mariani G. Anaplastic thyroid cancer: prevalence, diagnosis and treatment. Minerva Endocrinol 2008; 33: 341–357.
   PubMed Web of Science ®Google Scholar
• Richardson DB. Exposure to ionizing radiation in adulthood and thyroid cancer incidence. Epidemiology 2009; 20: 181–187.
   Web of Science ®Google Scholar
• Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411: 342–348.
   PubMed Web of Science ®Google Scholar
• Baverstock K, Egloff B, Pinchera A, Ruchti C, Williams D. Thyroid cancer after Chernobyl. Nature 1992; 359: 21–22.
   PubMed Web of Science ®Google Scholar
• Williams D. Cancer after nuclear fallout: lessons from the Chernobyl accident. Nat Rev Cancer 2002; 2: 543–549.
   PubMed Web of Science ®Google Scholar
• Belfiore A, Russo D, Vigneri R, Filetti S. Graves’ disease, thyroid nodules and thyroid cancer. Clin Endocrinol (Oxf) 2001; 55: 711–718.
   PubMed Web of Science ®Google Scholar
• Schaller RT, Jr Stevenson, JK. Development of carcinoma of the thyroid in iodine-deficient mice. Cancer 1966; 19: 1063–1080.
   PubMed Web of Science ®Google Scholar
• Fortner JG, George PA, Sternberg SS. Induced and spontaneous thyroid cancer in the Syrian (golden) hamster. Endocrinology 1960; 6: 364–376.
   Google Scholar
• Boltze C, Brabant G, Dralle H, Gerlach R, Roessner A, Hoang-Vu C. Radiation-induced thyroid carcinogenesis as a function of time and dietary iodine supply: an in vivo model of tumorigenesis in the rat. Endocrinology 2002; 143: 2584–2592.
   PubMed Web of Science ®Google Scholar
• Kanno J, Onodera H, Furuta K, Maekawa A, Kasuga T, Hayashi Y. Tumor-promoting effects of both iodine deficiency and iodine excess in the rat thyroid. Toxicol Pathol 1992; 20: 226–235.
   PubMed Web of Science ®Google Scholar
• Nishikawa A, Ikeda T, Son HY, Okazaki K, Imazawa T, Umemura T, Kimura S, Hirose M. Pronounced synergistic promotion of N-bis(2-hydroxypropyl)nitrosamine-initiated thyroid tumorigenesis in rats treated with excess soybean and iodine-deficient diets. Toxicol Sci 2005; 86: 258–263.
   PubMedGoogle Scholar
• Williams ED, Abrosimov A, Bogdanova T, Demidchik EP, Ito M, LiVolsi V, Lushnikov E, Rosai J, Tronko MD, Tsyb AF, Vowler SL, Thomas GA. Morphologic characteristics of Chernobyl-related childhood papillary thyroid carcinomas are independent of radiation exposure but vary with iodine intake. Thyroid 2008; 18: 847–852.
   PubMed Web of Science ®Google Scholar
• Song Y, Driessens N, Costa M, De Deken X, Detours V, Corvilain B, Maenhaut C, Miot F, Van Sande J, Many MC, Dumont JE. Roles of hydrogen peroxide in thyroid physiology and disease. J Clin Endocrinol Metab 2007; 92: 3764–3773.
   PubMed Web of Science ®Google Scholar
• De Deken X, Wang D, Dumont JE, Miot F. Characterization of ThOX proteins as components of the thyroid H2O2-generating system. Exp Cell Res 2002; 273: 187–196.
   PubMedGoogle Scholar
• Dupuy C, Virion A, Ohayon R, Kaniewski J, Deme D, Pommier J. Mechanism of hydrogen peroxide formation catalyzed by NADPH oxidase in thyroid plasma membrane. J Biol Chem 1991; 266: 3739–3743.
   PubMed Web of Science ®Google Scholar
• Venturi S, Donati FM, Venturi A, Venturi M, Grossi L, Guidi A. Role of iodine in evolution and carcinogenesis of thyroid, breast and stomach. Adv Clin Path 2000; 4: 11–17.
   PubMedGoogle Scholar
• Smyth PP. Role of iodine in antioxidant defence in thyroid and breast disease. Biofactors 2003; 19: 121–130.
   PubMed Web of Science ®Google Scholar
• Ohayon R, Boeynaems JM, Braekman JC, Van den Bergen H, Gorin Y, Virion A. Inhibition of thyroid NADPH-oxidase by 2-iodohexadecanal in a cell-free system. Mol Cell Endocrinol 1994; 99: 133–141.
   PubMed Web of Science ®Google Scholar
• Cardoso LC, Martins DC, Figueiredo MD, Rosenthal D, Vaisman M, Violante AH, Carvalho DP. Ca2+/nicotinamide adenine dinucleotide phosphate-dependent H2O2 generation is inhibited by iodide in human thyroids. J Clin Endocrinol Metab 2001; 86: 4339–4343.
   PubMed Web of Science ®Google Scholar
• Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J 2003; 17: 1195–1214.
   PubMed Web of Science ®Google Scholar
• Kupper FC, Carpenter LJ, McFiggans GB, Palmer CJ, Waite TJ, Boneberg EM, Woitsch S, Weiller M, Abela R, Grolimund D, Potin P, Butler A, Luther GW 3rd, Kroneck PM, Meyer-Klaucke W, Feiters MC. Iodide accumulation provides kelp with an inorganic antioxidant impacting atmospheric chemistry. Proc Natl Acad Sci USA 2008; 105: 6954–6958.
   PubMed Web of Science ®Google Scholar
• Fox MS, Klawansky S. Interruption of cell transformation and cancer formation. FASEB J 2006; 20: 2209–2213.
   Google Scholar
• Wiseman SM, Loree TR, Rigual NR, Hicks WL Jr, Douglas WG, Anderson GR, Stoler DL. Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy. Head Neck 2003; 25: 662–670.
   PubMedGoogle Scholar
• Wiseman SM, Griffith OL, Deen S, Rajput A, Masoudi H, Gilks B, Goldstein L, Gown A, Jones SJ. Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch Surg 2007; 142: 717–727; discussion 727–729.
   PubMedGoogle Scholar
• Ozaki O, Ito K, Mimura T, Sugino K. Anaplastic transformation of papillary thyroid carcinoma in recurrent disease in regional lymph nodes: a histologic and immunohistochemical study. J Surg Oncol 1999; 70: 45–48.
   Google Scholar
• Wang HM, Huang YW, Huang JS, Wang CH, Kok VC, Hung CM, Chen HM, Tzen CY. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma. Ann Surg Oncol 2007; 14: 3011–3018.
   Web of Science ®Google Scholar
• Mooradian AD, Allam CK, Khalil MF, Salti I, Salem PA. Anaplastic transformation of thyroid cancer: report of two cases and review of the literature. J Surg Oncol 1983; 23: 95–98.
   Google Scholar
• Takeshita Y, Takamura T, Minato H, Misu H, Ando H, Yamashita T, Ikeda H, Nakanuma Y, Kaneko S. Transformation of p53-positive papillary thyroid carcinoma to anaplastic carcinoma of the liver following postoperative radioactive iodine-131 therapy. Intern Med 2008; 47: 1709–1712.
   Google Scholar
• Rodrigues RF, Roque L, Rosa-Santos J, Cid O, Soares J. Chromosomal imbalances associated with anaplastic transformation of follicular thyroid carcinomas. Br J Cancer 2004; 90: 492–496.
   Google Scholar
• Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, Zhang Y, Bai Y, Zhu C, Guo GL, Rothman N. International patterns and trends in thyroid cancer incidence, 1973–2002. Cancer Causes Control 2009; 20: 525–531.
   PubMed Web of Science ®Google Scholar
• Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 2006; 295: 2164–2167.
   PubMed Web of Science ®Google Scholar
• Liu S, Semenciw R, Ugnat AM, Mao Y. Increasing thyroid cancer incidence in Canada, 1970–1996: time trends and age-period-cohort effects. Br J Cancer 2001; 85: 1335–1339.
   PubMed Web of Science ®Google Scholar
• Colonna M, Guizard AV, Schvartz C, Velten M, Raverdy N, Molinie F, Delafosse P, Franc B, Grosclaude P. A time trend analysis of papillary and follicular cancers as a function of tumour size: a study of data from six cancer registries in France (1983–2000). Eur J Cancer 2007; 43: 891–900.
   PubMed Web of Science ®Google Scholar
• Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 2006; 295: 2164–2167.
   PubMed Web of Science ®Google Scholar
• Grodski S, Brown T, Sidhu S, Gill A, Robinson B, Learoyd D, Sywak M, Reeve T, Delbridge L. Increasing incidence of thyroid cancer is due to increased pathologic detection. Surgery 2008; 144: 1038–1043.
   PubMed Web of Science ®Google Scholar
• Leenhardt L, Bernier MO, Boin-Pineau MH, Conte Devolx B, Marechaud R, Niccoli-Sire P, Nocaudie M, Orgiazzi J, Schlumberger M, Wemeau JL, Cherie-Challine L, De Vathaire F. Advances in diagnostic practices affect thyroid cancer incidence in France. Eur J Endocrinol 2004; 150: 133–139.
   PubMed Web of Science ®Google Scholar
• Hodgson NC, Button J, Solorzano CC. Thyroid cancer: is the incidence still increasing? Ann Surg Oncol 2004; 11: 1093–1097.
   PubMed Web of Science ®Google Scholar
• Guan H, Ji M, Bao R, Yu H, Wang Y, Hou P, Zhang Y, Shan Z, Teng W, Xing M. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab 2009; 94: 1612–1617.
   PubMed Web of Science ®Google Scholar
• Harach HR, Ceballos GA. Thyroid cancer, thyroiditis and dietary iodine: a review based on the Salta, Argentina model. Endocr Pathol 2008; 19: 209–220.
   PubMed Web of Science ®Google Scholar
• Lind P, Langsteger W, Molnar M, Gallowitsch HJ, Mikosch P, Gomez I. Epidemiology of thyroid diseases in iodine sufficiency. Thyroid 1998; 8: 1179–1183.
   PubMed Web of Science ®Google Scholar
• Pettersson B, Coleman MP, Ron E, Adami HO. Iodine supplementation in Sweden and regional trends in thyroid cancer incidence by histopathologic type. Int J Cancer 1996; 65: 13–19.
   Google Scholar
• Sehestedt T, Knudsen N, Perrild H, Johansen C. Iodine intake and incidence of thyroid cancer in Denmark. Clin Endocrinol (Oxf) 2006; 65: 229–233.
   Google Scholar
• Delange F, Lecomte P. Iodine supplementation: benefits outweigh risks. Drug Saf 2000; 22: 89–95.
   PubMed Web of Science ®Google Scholar
• Kapp DS, LiVolsi VA, Sanders MM. Anaplastic carcinoma following well-differentiated thyroid cancer: etiological considerations. Yale J Biol Med 1982; 55: 521–528.
   Google Scholar
• Smerdely P, Pitsiavas V, Boyages SC. Evidence that the inhibitory effects of iodide on thyroid cell proliferation are due to arrest of the cell cycle at G0G1 and G2M phases. Endocrinology 1993; 133: 2881–2888.
   PubMedGoogle Scholar
• Tramontano D, Veneziani BM, Lombardi A, Villone G, Ingbar SH. Iodine inhibits the proliferation of rat thyroid cells in culture. Endocrinology 1989; 125: 984–992.
   Google Scholar
• Eskin BA, Shuman R, Krouse T, Merion JA. Rat mammary gland atypia produced by iodine blockade with perchlorate. Cancer Res 1975; 35: 2332–2339.
   PubMed Web of Science ®Google Scholar
• Unger J, Lambert M, Jonckheer MH, Denayer P. Amiodarone and the thyroid: pharmacological, toxic and therapeutic effects. J Intern Med 1993; 233: 435–443.
   Google Scholar
• Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev 2001; 22: 240–254.
   PubMed Web of Science ®Google Scholar
• Mahmoud I, Colin I, Many MC, Denef JF. Direct toxic effect of iodide in excess on iodine-deficient thyroid glands: epithelial necrosis and inflammation associated with lipofuscin accumulation. Exp Mol Pathol 1986; 44: 259–271.
   PubMed Web of Science ®Google Scholar
• Filetti S, Rapoport B. Evidence that organic iodine attenuates the adenosine 3′,5′-monophosphate response to thyrotropin stimulation in thyroid tissue by an action at or near the adenylate cyclase catalytic unit. Endocrinology 1983; 113: 1608–1615.
   PubMed Web of Science ®Google Scholar
• Yuasa R, Eggo MC, Meinkoth J, Dillmann WH, Burrow GN. Iodide induces transforming growth factor beta 1 (TGF-beta 1) mRNA in sheep thyroid cells. Thyroid 1992; 2: 141–145.
   Google Scholar
• Pang XP, Park M, Hershman JM. Transforming growth factor-beta blocks protein kinase-A-mediated iodide transport and protein kinase-C-mediated DNA synthesis in FRTL-5 rat thyroid cells. Endocrinology 1992; 131: 45–50.
   PubMed Web of Science ®Google Scholar
• Bidey SP. Control of thyroid cell and follicle growth. Recent advances and current controversies. Trends Endocrinol Metab 1990; 1: 174–178.
   Google Scholar
• Golstein J, Dumont JE. Cytotoxic effects of iodide on thyroid cells: difference between rat thyroid FRTL-5 cell and primary dog thyrocyte responsiveness. J Endocrinol Invest 1996; 19: 119–126.
   Google Scholar
• Huang M, Batra RK, Kogai T, Lin YQ, Hershman JM, Lichtenstein A, Sharma S, Zhu LX, Brent GA, Dubinett SM. Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Gene Ther 2001; 8: 612–618.
   PubMed Web of Science ®Google Scholar
• Zhang L, Sharma S, Zhu LX, Kogai T, Hershman JM, Brent GA, Dubinett SM, Huang M. Nonradioactive iodide effectively induces apoptosis in genetically modified lung cancer cells. Cancer Res 2003; 63: 5065–5072.
   PubMed Web of Science ®Google Scholar
• Garcia-Solis P, Alfaro Y, Anguiano B, Delgado G, Guzman RC, Nandi S, Diaz-Munoz M, Vazquez-Martinez O, Aceves C. Inhibition of N-methyl-N-nitrosourea-induced mammary carcinogenesis by molecular iodine (I2) but not by iodide (I−) treatment. Evidence that I2 prevents cancer promotion. Mol Cell Endocrinol 2005; 236: 49–57.
   PubMed Web of Science ®Google Scholar
• Shrivastava A, Tiwari M, Sinha RA, Kumar A, Balapure AK, Bajpai VK, Sharma R, Mitra K, Tandon A, Godbole MM. Molecular iodine induces caspase-independent apoptosis in human breast carcinoma cells involving the mitochondria-mediated pathway. J Biol Chem 2006; 281: 19762–19771.
   PubMed Web of Science ®Google Scholar
• Langer R, Burzler C, Bechtner G, Gartner R. Influence of iodide and iodolactones on thyroid apoptosis. Evidence that apoptosis induced by iodide is mediated by iodolactones in intact porcine thyroid follicles. Exp Clin Endocrinol Diabetes 2003; 111: 325–329.
   PubMed Web of Science ®Google Scholar
• Upadhyay G, Singh R, Sharma R, Balapure AK, Godbole MM. Differential action of iodine on mitochondria from human tumoral- and extra-tumoral tissue in inducing the release of apoptogenic proteins. Mitochondrion 2002; 2: 199–210.
   Google Scholar
• Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005; 12: 245–262.
   PubMed Web of Science ®Google Scholar
• Henderson YC, Shellenberger TD, Williams MD, El-Naggar AK, Fredrick MJ, Cieply KM, Clayman GL. High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res 2009; 15: 485–491.
   PubMed Web of Science ®Google Scholar
• Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003; 88: 5399–5404.
   PubMed Web of Science ®Google Scholar
• Takano T, Ito Y, Hirokawa M, Yoshida H, Miyauchi A. BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas. Br J Cancer 2007; 96: 1549–1553.
   Google Scholar
• Takahashi K, Eguchi H, Arihiro K, Ito R, Koyama K, Soda M, Cologne J, Hayashi Y, Nakata Y, Nakachi K, Hamatani K. The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose. Mol Carcinog 2007; 46: 242–248.
   Google Scholar
• Oler G, Cerutti JM. High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer 2009; 115: 972–980.
   PubMed Web of Science ®Google Scholar
• Romei C, Ciampi R, Faviana P, Agate L, Molinaro E, Bottici V, Basolo F, Miccoli P, Pacini F, Pinchera A, Elisei R. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr Relat Cancer 2008; 15: 511–520.
   PubMedGoogle Scholar
• Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E, Cavaliere A, Gulino A, Filetti S, Russo D. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 2007; 92: 2840–2843.
   PubMed Web of Science ®Google Scholar
• Espadinha C, Santos JR, Sobrinho LG, Bugalho MJ. Expression of iodine metabolism genes in human thyroid tissues: evidence for age and BRAF(V600E) mutation dependency. Clin Endocrinol (Oxf) 2009; 70: 629–635.
   PubMedGoogle Scholar
• Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, Refetoff S, Nikiforov YE, Fagin JA. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 2005; 65: 4238–4245.
   PubMed Web of Science ®Google Scholar
• Henderson YC, Fredrick MJ, Clayman GL. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors. Arch Otolaryngol Head Neck Surg 2007; 133: 810–815.
   Google Scholar
• Leboeuf R, Baumgartner JE, Benezra M, Malaguarnera R, Solit D, Pratilas CA, Rosen N, Knauf JA, Fagin JA. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab 2008; 93: 2194–2201.
   PubMed Web of Science ®Google Scholar
• Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, El-Naggar AK, Xing M. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 2008; 93: 3106–3116.
   PubMed Web of Science ®Google Scholar
• Namba H, Saenko V, Yamashita S. Nuclear factor-kB in thyroid carcinogenesis and progression: a novel therapeutic target for advanced thyroid cancer. Arq Bras Endocrinol Metabol 2007; 51: 843–851.
   Google Scholar
• Mitsiades CS, Negri J, McMullan C, McMillin DW, Sozopoulos E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Poulaki V, Batt D, Mitsiades N. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications. Mol Cancer Ther 2007; 6: 1070–1078.
   PubMedGoogle Scholar
• Mian C, Barollo S, Pennelli G, Pavan N, Rugge M, Pelizzo MR, Mazzarotto R, Casara D, Nacamulli D, Mantero F, Opocher G, Busnardo B, Girelli ME. Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin Endocrinol (Oxf) 2008; 68: 108–116.
   PubMed Web of Science ®Google Scholar
• Durand S, Ferraro-Peyret C, Joufre M, Chave A, Borson-Chazot F, Selmi-Ruby S, Rousset B. Molecular characteristics of papillary thyroid carcinomas without BRAF mutation or RET/PTC rearrangement. Relationship with clinicopathological features. Endocr Relat Cancer 2009; 16: 467–481.
   Google Scholar
• Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006; 6: 292–306.
   PubMed Web of Science ®Google Scholar
• Hamatani K, Eguchi H, Ito R, Mukai M, Takahashi K, Taga M, Imai K, Cologne J, Soda M, Arihiro K, Fujihara M, Abe K, Hayashi T, Nakashima M, Sekine I, Yasui W, Hayashi Y, Nakachi K. RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose. Cancer Res 2008; 68: 7176–7182.
   PubMed Web of Science ®Google Scholar
• Nakashima M, Takamura N, Namba H, Saenko V, Meirmanov S, Matsumoto N, Hayashi T, Maeda S, Sekine I. RET oncogene amplification in thyroid cancer: correlations with radiation-associated and high-grade malignancy. Hum Pathol 2007; 38: 621–628.
   Google Scholar
• Rabes HM, Demidchik EP, Sidorow JD, Lengfelder E, Beimfohr C, Hoelzel D, Klugbauer S. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-Chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin Cancer Res 2000; 6: 1093–1103.
   PubMed Web of Science ®Google Scholar
• Gujral TS, van Veelen W, Richardson DS, Myers SM, Meens JA, Acton DS, Dunach M, Elliott BE, Hoppener JW, Mulligan LM. A novel RET kinase-beta-catenin signaling pathway contributes to tumorigenesis in thyroid carcinoma. Cancer Res 2008; 68: 1338–1346.
   PubMedGoogle Scholar
• Kim DW, Chung HK, Park KC, Hwang JH, Jo YS, Chung J, Kalvakolanu DV, Resta N, Shong M. Tumor suppressor LKB1 inhibits activation of signal transducer and activator of transcription 3 (STAT3) by thyroid oncogenic tyrosine kinase rearranged in transformation (RET)/papillary thyroid carcinoma (PTC). Mol Endocrinol 2007; 21: 3039–3049.
   PubMedGoogle Scholar
• Kim YR, Byun HS, Won M, Park KA, Kim JM, Choi BL, Lee H, Hong JH, Park J, Seok JH, Kim DW, Shong M, Park SK, Hur GM. Modulatory role of phospholipase D in the activation of signal transducer and activator of transcription (STAT)-3 by thyroid oncogenic kinase RET/PTC. BMC Cancer 2008; 8: 144–154.
   PubMedGoogle Scholar
• Suchy B, Waldmann V, Klugbauer S, Rabes HM. Absence of RAS and p53 mutations in thyroid carcinomas of children after Chernobyl in contrast to adult thyroid tumours. Br J Cancer 1998; 77: 952–955.
   Google Scholar
• Shi YF, Zou MJ, Schmidt H, Juhasz F, Stensky V, Robb D, Farid NR. High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area. Cancer Res 1991; 51: 2690–2693.
   Google Scholar
• Garcia-Silva S, Aranda A. The thyroid hormone receptor is a suppressor of ras-mediated transcription, proliferation, and transformation. Mol Cell Biol 2004; 24: 7514–7523.
   PubMed Web of Science ®Google Scholar
• Vitagliano D, Portella G, Troncone G, Francione A, Rossi C, Bruno A, Giorgini A, Coluzzi S, Nappi TC, Rothstein JL, Pasquinelli R, Chiappetta G, Terracciano D, Macchia V, Melillo RM, Fusco A, Santoro M. Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas. Oncogene 2006; 25: 5467–5474.
   Google Scholar
• Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M, Orntoft T, Fusco A, Santoro M. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 2005; 115: 1068–1081.
   PubMed Web of Science ®Google Scholar
• Cass LA, Meinkoth JL. Ras signaling through PI3K confers hormone-independent proliferation that is compatible with differentiation. Oncogene 2000; 19: 924–932.
   PubMed Web of Science ®Google Scholar
• Liu D, Liu Z, Jiang D, Dackiw AP, Xing M. Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations. J Clin Endocrinol Metab 2007; 92: 4686–4695.
   PubMedGoogle Scholar
• Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G, Vasko V, Xing M. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 2007; 13: 1161–1170.
   PubMed Web of Science ®Google Scholar
• Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J, Tallini G. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 2003; 21: 3226–3235.
   PubMed Web of Science ®Google Scholar
• Brzezianska E, Karbownik M, Migdalska-Sek M, Pastuszak-Lewandoska D, Wloch J, Lewinski A. Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population. Mutat Res 2006; 599: 26–35.
   PubMed Web of Science ®Google Scholar
• Brzezianska E, Pastuszak-Lewandoska D, Lewinski A. Rearrangements of NTRK1 oncogene in papillary thyroid carcinoma. Neuro Endocrinol Lett 2007; 28: 221–229.
   Google Scholar
• Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S, Pierotti MA, Greco A. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 2004; 23: 7436–7440.
   PubMed Web of Science ®Google Scholar
• Beimfohr C, Klugbauer S, Demidchik EP, Lengfelder E, Rabes HM. NTRK1 re-arrangement in papillary thyroid carcinomas of children after the Chernobyl reactor accident. Int J Cancer 1999; 80: 842–847.
   PubMed Web of Science ®Google Scholar
• Musholt TJ, Brehm C, Hanack J, von Wasielewski R, Musholt PB. Identification of differentially expressed genes in papillary thyroid carcinomas with and without rearrangements of the tyrosine kinase receptors RET and/or NTRK1. J Surg Res 2006; 131: 15–25.
   Google Scholar
• Musholt TJ, Musholt PB, Khaladj N, Schulz D, Scheumann GF, Klempnauer J. Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma. Surgery 2000; 128: 984–993.
   PubMed Web of Science ®Google Scholar
• Barzon L, Gnatta E, Castagliuolo I, Trevisan M, Moretti F, Pontecorvi A, Boscaro M, Palu G. Modulation of retrovirally driven therapeutic genes by mutant TP53 in anaplastic thyroid carcinoma. Cancer Gene Ther 2005; 12: 381–388.
   Web of Science ®Google Scholar
• Ito Y, Motoo Y, Yoshida H, Iovanna JL, Nakamura Y, Kuma K, Miyauchi A. High level of tumour protein p53-induced nuclear protein 1 (TP53INP1) expression in anaplastic carcinoma of the thyroid. Pathology 2006; 38: 545–547.
   Google Scholar
• Moretti F, Farsetti A, Soddu S, Misiti S, Crescenzi M, Filetti S, Andreoli M, Sacchi A, Pontecorvi A. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene 1997; 14: 729–740.
   PubMed Web of Science ®Google Scholar
• Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer 2009; 9: 95–107.
   PubMed Web of Science ®Google Scholar
• Bachmann K, Pawliska D, Kaifi J, Schurr P, Zorb J, Mann O, Kahl HJ, Izbicki JR, Strate T. P53 is an independent prognostic factor for survival in thyroid cancer. Anticancer Res 2007; 27: 3993–3997.
   Google Scholar
• Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 2008; 21(Suppl 2): S37–S43.
   Google Scholar
• Tepmongkol S, Keelawat S, Honsawek S, Ruangvejvorachai P. Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma. Thyroid 2008; 18: 697–704.
   PubMed Web of Science ®Google Scholar
• Espadinha C, Cavaco BM, Leite V. PAX8PPARgamma stimulates cell viability and modulates expression of thyroid-specific genes in a human thyroid cell line. Thyroid 2007; 17: 497–509.
   Google Scholar
• Lui WO, Foukakis T, Liden J, Thoppe SR, Dwight T, Hoog A, Zedenius J, Wallin G, Reimers M, Larsson C. Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPARγ fusion oncogene. Oncogene 2005; 24: 1467–1476.
   PubMedGoogle Scholar
• Kato Y, Ying H, Zhao L, Furuya F, Araki O, Willingham MC, Cheng SY. PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathway. Oncogene 2006; 25: 2736–2747.
   PubMed Web of Science ®Google Scholar
• Sahin M, Allard BL, Yates M, Powell JG, Wang XL, Hay ID, Zhao Y, Goellner JR, Sebo TJ, Grebe SK, Eberhardt NL, McIver B. PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value. J Clin Endocrinol Metab 2005; 90: 463–468.
   PubMed Web of Science ®Google Scholar
• Guigon CJ, Zhao L, Lu C, Willingham MC, Cheng SY. Regulation of beta-catenin by a novel nongenomic action of thyroid hormone beta receptor. Mol Cell Biol 2008; 28: 4598–4608.
   PubMedGoogle Scholar
• Kim WB, Lewis CJ, McCall KD, Malgor R, Kohn AD, Moon RT, Kohn LD. Overexpression of Wnt-1 in thyrocytes enhances cellular growth but suppresses transcription of the thyroperoxidase gene via different signaling mechanisms. J Endocrinol 2007; 193: 93–106.
   PubMedGoogle Scholar
• Kitamura Y, Shimizu K, Tanaka S, Ito K, Emi M. Allelotyping of anaplastic thyroid carcinoma: frequent allelic losses on 1q, 9p, 11, 17, 19p, and 22q. Genes Chromosomes Cancer 2000; 27: 244–251.
   Google Scholar
• Abbosh PH, Nephew KP. Multiple signaling pathways converge on beta-catenin in thyroid cancer. Thyroid 2005; 15: 551–561.
   PubMedGoogle Scholar
• Abbosh PH, Li X, Li L, Gardner TA, Kao C, Nephew KP. A conditionally replicative, Wnt/beta-catenin pathway-based adenovirus therapy for anaplastic thyroid cancer. Cancer Gene Ther 2007; 14: 399–408.
   PubMed Web of Science ®Google Scholar
• Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL, Tallini G. Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 2001; 158: 987–996.
   PubMedGoogle Scholar
• Riesco-Eizaguirre G, Santisteban P. A perspective view of sodium iodide symporter research and its clinical implications. Eur J Endocrinol 2006; 155: 495–512.
   PubMed Web of Science ®Google Scholar
• Dadachova E, Carrasco N. The Na/I symporter (NIS): imaging and therapeutic applications. Semin Nucl Med 2004; 34: 23–31.
   PubMed Web of Science ®Google Scholar
• Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996; 379: 458–460.
   PubMed Web of Science ®Google Scholar
• Smanik PA, Ryu KY, Theil KS, Mazzaferri EL, Jhiang SM. Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology 1997; 138: 3555–3558.
   Google Scholar
• Scott DA, Wang R, Kreman TM, Sheffield VC, Karniski LP. The Pendred syndrome gene encodes a chloride-iodide transport protein. Nat Genet 1999; 21: 440–443.
   PubMed Web of Science ®Google Scholar
• Rodriguez AM, Perron B, Lacroix L, Caillou B, Leblanc G, Schlumberger M, Bidart JM, Pourcher T. Identification and characterization of a putative human iodide transporter located at the apical membrane of thyrocytes. J Clin Endocrinol Metab 2002; 87: 3500–3503.
   PubMed Web of Science ®Google Scholar
• Sarlis NJ. Metastatic thyroid cancer unresponsive to conventional therapies: novel management approaches through translational clinical research. Curr Drug Targets Immune Endocr Metabol Disord 2001; 1: 103–115.
   Google Scholar
• Giuffrida D, Gharib H. Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann Oncol 2000; 11: 1083–1089.
   PubMed Web of Science ®Google Scholar
• Trapasso F, Iuliano R, Chiefari E, Arturi F, Stella A, Filetti S, Fusco A, Russo D. Iodide symporter gene expression in normal and transformed rat thyroid cells. Eur J Endocrinol 1999; 140: 447–451.
   Google Scholar
• Ward LS, Santarosa PL, Granja F, da Assumpcao LV, Savoldi M, Goldman GH. Low expression of sodium iodide symporter identifies aggressive thyroid tumors. Cancer Lett 2003; 200: 85–91.
   PubMedGoogle Scholar
• Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006; 13: 453–464.
   PubMed Web of Science ®Google Scholar
• Baker CH, Morris JC. The sodium-iodide symporter. Curr Drug Targets Immune Endocr Metabol Disord 2004; 4: 167–174.
   PubMedGoogle Scholar
• Riedel C, Dohan O, De la Vieja A, Ginter CS, Carrasco N. Journey of the iodide transporter NIS: from its molecular identification to its clinical role in cancer. Trends Biochem Sci 2001; 26: 490–496.
   PubMed Web of Science ®Google Scholar
• Lazar V, Bidart JM, Caillou B, Mahe C, Lacroix L, Filetti S, Schlumberger M. Expression of the Na+/I− symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 1999; 84: 3228–3234.
   PubMed Web of Science ®Google Scholar
• Park HJ, Kim JY, Park KY, Gong G, Hong SJ, Ahn IM. Expressions of human sodium iodide symporter mRNA in primary and metastatic papillary thyroid carcinomas. Thyroid 2000; 10: 211–217.
   PubMed Web of Science ®Google Scholar
• Arturi F, Russo D, Schlumberger M, du Villard JA, Caillou B, Vigneri P, Wicker R, Chiefari E, Suarez HG, Filetti S. Iodide symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab 1998; 83: 2493–2496.
   PubMed Web of Science ®Google Scholar
• Mishra A, Pal L, Mishra SK. Distribution of Na+/I− symporter in thyroid cancers in an iodine-deficient population: an immunohistochemical study. World J Surg 2007; 31: 1737–1742.
   Google Scholar
• Wapnir IL, van de Rijn M, Nowels K, Amenta PS, Walton K, Montgomery K, Greco RS, Dohan O, Carrasco N. Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab 2003; 88: 1880–1888.
   PubMed Web of Science ®Google Scholar
• Saito T, Endo T, Kawaguchi A, Ikeda M, Katoh R, Kawaoi A, Muramatsu A, Onaya T. Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas. J Clin Invest 1998; 101: 1296–1300.
   Google Scholar
• Peyrottes I, Navarro V, Ondo-Mendez A, Marcellin D, Bellanger L, Marsault R, Lindenthal S, Ettore F, Darcourt J, Pourcher T. Immunoanalysis indicates that the sodium iodide symporter is not overexpressed in intracellular compartments in thyroid and breast cancers. Eur J Endocrinol 2009; 160: 215–225.
   Google Scholar
• Kogai T, Curcio F, Hyman S, Cornford EM, Brent GA, Hershman JM. Induction of follicle formation in long-term cultured normal human thyroid cells treated with thyrotropin stimulates iodide uptake but not sodium/iodide symporter messenger RNA and protein expression. J Endocrinol 2000; 167: 125–135.
   PubMed Web of Science ®Google Scholar
• Fujiwara H, Tatsumi K, Miki K, Harada T, Miyai K, Takai S, Amino N. Congenital hypothyroidism caused by a mutation in the Na+/I− symporter. Nat Genet 1997; 16: 124–125.
   PubMed Web of Science ®Google Scholar
• Fujiwara H, Tatsumi K, Miki K, Harada T, Okada S, Nose O, Kodama S, Amino N. Recurrent T354P mutation of the Na+/I− symporter in patients with iodide transport defect. J Clin Endocrinol Metab 1998; 83: 2940–2943.
   Google Scholar
• Kosugi S, Bhayana S, Dean HJ. A novel mutation in the sodium/iodide symporter gene in the largest family with iodide transport defect. J Clin Endocrinol Metab 1999; 84: 3248–3253.
   PubMed Web of Science ®Google Scholar
• Kosugi S, Okamoto H, Tamada A, Sanchez-Franco F. A novel peculiar mutation in the sodium/iodide symporter gene in Spanish siblings with iodide transport defect. J Clin Endocrinol Metab 2002; 87: 3830–3836.
   Google Scholar
• Kosugi S, Sato Y, Matsuda A, Ohyama Y, Fujieda K, Inomata H, Kameya T, Isozaki O, Jhiang SM. High prevalence of T354P sodium/iodide symporter gene mutation in Japanese patients with iodide transport defect who have heterogeneous clinical pictures. J Clin Endocrinol Metab 1998; 83: 4123–4129.
   Google Scholar
• Matsuda A, Kosugi S. A homozygous missense mutation of the sodium/iodide symporter gene causing iodide transport defect. J Clin Endocrinol Metab 1997; 82: 3966–3971.
   Google Scholar
• Pohlenz J, Medeiros-Neto G, Gross JL, Silveiro SP, Knobel M, Refetoff S. Hypothyroidism in a Brazilian kindred due to iodide trapping defect caused by a homozygous mutation in the sodium/iodide symporter gene. Biochem Biophys Res Commun 1997; 240: 488–491.
   Google Scholar
• De La Vieja A, Ginter CS, Carrasco N. The Q267E mutation in the sodium/iodide symporter (NIS) causes congenital iodide transport defect (ITD) by decreasing the NIS turnover number. J Cell Sci 2004; 117: 677–687.
   Google Scholar
• Szinnai G, Kosugi S, Derrien C, Lucidarme N, David V, Czernichow P, Polak M. Extending the clinical heterogeneity of iodide transport defect (ITD): a novel mutation R124H of the sodium/iodide symporter gene and review of genotype-phenotype correlations in ITD. J Clin Endocrinol Metab 2006; 91: 1199–1204.
   Google Scholar
• Russo D, Manole D, Arturi F, Suarez HG, Schlumberger M, Filetti S, Derwahl M. Absence of sodium/iodide symporter gene mutations in differentiated human thyroid carcinomas. Thyroid 2001; 11: 37–39.
   Google Scholar
• Sodre AK, Rubio IG, Galrao AL, Knobel M, Tomimori EK, Alves VA, Kanamura CT, Buchpiguel CA, Watanabe T, Friguglietti CU, Kulcsar MA, Medeiros-Neto G, Camargo RY. Association of low sodium-iodide symporter messenger ribonucleic acid expression in malignant thyroid nodules with increased intracellular protein staining. J Clin Endocrinol Metab 2008; 93: 4141–4145.
   PubMed Web of Science ®Google Scholar
• Dohan O, Baloch Z, Banrevi Z, Livolsi V, Carrasco N. Predominant intracellular overexpression of the Na+/I− symporter (NIS) in a large sampling of thyroid cancer cases. J Clin Endocrinol Metab 2001; 86: 2697–2700.
   Google Scholar
• Kogai T, Taki K, Brent GA. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer 2006; 13: 797–826.
   PubMed Web of Science ®Google Scholar
• Arturi F, Presta I, Scarpelli D, Bidart JM, Schlumberger M, Filetti S, Russo D. Stimulation of iodide uptake by human chorionic gonadotropin in FRTL-5 cells: effects on sodium/iodide symporter gene and protein expression. Eur J Endocrinol 2002; 147: 655–661.
   Google Scholar
• van Hoek I, Daminet S, Vandermeulen E, Dobbeleir A, Duchateau L, Peremans K. Recombinant human thyrotropin administration enhances thyroid uptake of radioactive iodine in hyperthyroid cats. J Vet Intern Med 2008; 22: 1340–1344.
   Google Scholar
• Coelho SM, Vaisman M, Carvalho DP. Tumour re-differentiation effect of retinoic acid: a novel therapeutic approach for advanced thyroid cancer. Curr Pharm Des 2005; 11: 2525–2531.
   Google Scholar
• Kurebayashi J, Tanaka K, Otsuki T, Moriya T, Kunisue H, Uno M, Sonoo H. All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. J Clin Endocrinol Metab 2000; 85: 2889–2896.
   Google Scholar
• Schumm-Draeger PM. Sodium/iodide symporter (NIS) and cytokines. Exp Clin Endocrinol Diabetes 2001; 109: 32–34.
   PubMedGoogle Scholar
• Kawaguchi A, Ikeda M, Endo T, Kogai T, Miyazaki A, Onaya T. Transforming growth factor-beta1 suppresses thyrotropin-induced Na+/I− symporter messenger RNA and protein levels in FRTL-5 rat thyroid cells. Thyroid 1997; 7: 789–794.
   PubMedGoogle Scholar
• Spitzweg C, Joba W, Morris JC, Heufelder AE. Regulation of sodium iodide symporter gene expression in FRTL-5 rat thyroid cells. Thyroid 1999; 9: 821–830.
   PubMedGoogle Scholar
• Fortunati N, Catalano MG, Arena K, Brignardello E, Piovesan A, Boccuzzi G. Valproic acid induces the expression of the Na+/I− symporter and iodine uptake in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 2004; 89: 1006–1009.
   PubMed Web of Science ®Google Scholar
• Catalano MG, Fortunati N, Pugliese M, Costantino L, Poli R, Bosco O, Boccuzzi G. Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 2005; 90: 1383–1389.
   PubMed Web of Science ®Google Scholar
• Kitazono M, Robey R, Zhan Z, Sarlis NJ, Skarulis MC, Aikou T, Bates S, Fojo T. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na+/I− symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 2001; 86: 3430–3435.
   PubMed Web of Science ®Google Scholar
• Akagi T, Luong QT, Gui D, Said J, Selektar J, Yung A, Bunce CM, Braunstein GD, Koeffler HP. Induction of sodium iodide symporter gene and molecular characterisation of HNF3 beta/FoxA2, TTF-1 and C/EBP beta in thyroid carcinoma cells. Br J Cancer 2008; 99: 781–788.
   PubMed Web of Science ®Google Scholar
• Vassart G, Dumont JE. The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr Rev 1992; 13: 596–611.
   PubMed Web of Science ®Google Scholar
• Levy O, Dai G, Riedel C, Ginter CS, Paul EM, Lebowitz AN, Carrasco N. Characterization of the thyroid Na+/I− symporter with an anti-COOH terminus antibody. Proc Natl Acad Sci USA 1997; 94: 5568–5573.
   PubMed Web of Science ®Google Scholar
• Kogai T, Endo T, Saito T, Miyazaki A, Kawaguchi A, Onaya T. Regulation by thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein levels in FRTL-5 cells. Endocrinology 1997; 138: 2227–2232.
   PubMed Web of Science ®Google Scholar
• Weiss SJ, Philp NJ, Ambesi-Impiombato FS, Grollman EF. Thyrotropin-stimulated iodide transport mediated by adenosine 3′,5′-monophosphate and dependent on protein synthesis. Endocrinology 1984; 114: 1099–1107.
   PubMed Web of Science ®Google Scholar
• Ohno M, Zannini M, Levy O, Carrasco N, di Lauro R. The paired-domain transcription factor Pax8 binds to the upstream enhancer of the rat sodium/iodide symporter gene and participates in both thyroid-specific and cyclic-AMP-dependent transcription. Mol Cell Biol 1999; 19: 2051–2060.
   PubMedGoogle Scholar
• Riedel C, Levy O, Carrasco N. Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin. J Biol Chem 2001; 276: 21458–21463.
   PubMed Web of Science ®Google Scholar
• Chun JT, Di Dato V, D’Andrea B, Zannini M, Di Lauro R. The CRE-like element inside the 5′-upstream region of the rat sodium/iodide symporter gene interacts with diverse classes of b-Zip molecules that regulate transcriptional activities through strong synergy with Pax-8. Mol Endocrinol 2004; 18: 2817–2829.
   Google Scholar
• Endo T, Kaneshige M, Nakazato M, Ohmori M, Harii N, Onaya T. Thyroid transcription factor-1 activates the promoter activity of rat thyroid Na+/I− symporter gene. Mol Endocrinol 1997; 11: 1747–1755.
   PubMedGoogle Scholar
• Taki K, Kogai T, Kanamoto Y, Hershman JM, Brent GA. A thyroid-specific far-upstream enhancer in the human sodium/iodide symporter gene requires Pax-8 binding and cyclic adenosine 3′,5′-monophosphate response element-like sequence binding proteins for full activity and is differentially regulated in normal and thyroid cancer cells. Mol Endocrinol 2002; 16: 2266–2282.
   PubMedGoogle Scholar
• Presta I, Arturi F, Ferretti E, Mattei T, Scarpelli D, Tosi E, Scipioni A, Celano M, Gulino A, Filetti S, Russo D. Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene. BMC Cancer 2005; 5: 80–89.
   Google Scholar
• Furuya F, Shimura H, Miyazaki A, Taki K, Ohta K, Haraguchi K, Onaya T, Endo T, Kobayashi T. Adenovirus-mediated transfer of thyroid transcription factor-1 induces radioiodide organification and retention in thyroid cancer cells. Endocrinology 2004; 145: 5397–5405.
   Web of Science ®Google Scholar
• Bruno R, Ferretti E, Tosi E, Arturi F, Giannasio P, Mattei T, Scipioni A, Presta I, Morisi R, Gulino A, Filetti S, Russo D. Modulation of thyroid-specific gene expression in normal and nodular human thyroid tissues from adults: an in vivo effect of thyrotropin. J Clin Endocrinol Metab 2005; 90: 5692–5697.
   Google Scholar
• Kogai T, Sajid-Crockett S, Newmarch LS, Liu YY, Brent GA. Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells. J Endocrinol 2008; 199: 243–252.
   PubMedGoogle Scholar
• Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA, McCubrey JA. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003; 17: 590–603.
   PubMed Web of Science ®Google Scholar
• Rivas M, Santisteban P. TSH-activated signaling pathways in thyroid tumorigenesis. Mol Cell Endocrinol 2003; 213: 31–45.
   PubMed Web of Science ®Google Scholar
• Paes JE, Ringel MD. Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol Metab Clin North Am 2008; 37: 375–387.
   PubMedGoogle Scholar
• Hoffmann S, Maschuw K, Hassan I, Wunderlich A, Lingelbach S, Ramaswamy A, Hofbauer LC, Zielke A. Functional thyrotropin receptor attenuates malignant phenotype of follicular thyroid cancer cells. Endocrine 2006; 30: 129–138.
   PubMed Web of Science ®Google Scholar
• Milas M, Mazzaglia P, Chia SY, Skugor M, Berber E, Reddy S, Gupta M, Siperstein A. The utility of peripheral thyrotropin mRNA in the diagnosis of follicular neoplasms and surveillance of thyroid cancers. Surgery 2007; 141: 137–146; discussion 146.
   PubMed Web of Science ®Google Scholar
• Matsumoto H, Sakamoto A, Fujiwara M, Yano Y, Shishido-Hara Y, Fujioka Y, Kamma H. Decreased expression of the thyroid-stimulating hormone receptor in poorly-differentiated carcinoma of the thyroid. Oncol Rep 2008; 19: 1405–1411.
   Google Scholar
• Xing M, Usadel H, Cohen Y, Tokumaru Y, Guo Z, Westra WB, Tong BC, Tallini G, Udelsman R, Califano JA, Ladenson PW, Sidransky D. Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res 2003; 63: 2316–2321.
   PubMed Web of Science ®Google Scholar
• Brabant G, Maenhaut C, Kohrle J, Scheumann G, Dralle H, Hoang-Vu C, Hesch RD, von zur Muhlen A, Vassart G, Dumont JE. Human thyrotropin receptor gene: expression in thyroid tumors and correlation to markers of thyroid differentiation and dedifferentiation. Mol Cell Endocrinol 1991; 82: R7–R12.
   Google Scholar
• Elisei R, Pinchera A, Romei C, Gryczynska M, Pohl V, Maenhaut C, Fugazzola L, Pacini F. Expression of thyrotropin receptor (TSH-R), thyroglobulin, thyroperoxidase, and calcitonin messenger ribonucleic acids in thyroid carcinomas: evidence of TSH-R gene transcript in medullary histotype. J Clin Endocrinol Metab 1994; 78: 867–871.
   PubMed Web of Science ®Google Scholar
• Lin JD. Thyroglobulin and human thyroid cancer. Clin Chim Acta 2008; 388: 15–21.
   PubMed Web of Science ®Google Scholar
• Giovanella L. Highly sensitive thyroglobulin measurements in differentiated thyroid carcinoma management. Clin Chem Lab Med 2008; 46: 1067–1073.
   Google Scholar
• Spencer CA, Lopresti JS. Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. Nat Clin Pract Endocrinol Metab 2008; 4: 223–233.
   PubMedGoogle Scholar
• Kohn LD, Suzuki K, Nakazato M, Royaux I, Green ED. Effects of thyroglobulin and pendrin on iodide flux through the thyrocyte. Trends Endocrinol Metab 2001; 12: 10–16.
   PubMedGoogle Scholar
• Suzuki K, Lavaroni S, Mori A, Ohta M, Saito J, Pietrarelli M, Singer DS, Kimura S, Katoh R, Kawaoi A, Kohn LD. Autoregulation of thyroid-specific gene transcription by thyroglobulin. Proc Natl Acad Sci USA 1998; 95: 8251–8256.
   PubMedGoogle Scholar
• Suzuki K, Mori A, Saito J, Moriyama E, Ullianich L, Kohn LD. Follicular thyroglobulin suppresses iodide uptake by suppressing expression of the sodium/iodide symporter gene. Endocrinology 1999; 140: 5422–5430.
   PubMed Web of Science ®Google Scholar
• Eng PH, Cardona GR, Fang SL, Previti M, Alex S, Carrasco N, Chin WW, Braverman LE. Escape from the acute Wolff-Chaikoff effect is associated with a decrease in thyroid sodium/iodide symporter messenger ribonucleic acid and protein. Endocrinology 1999; 140: 3404–3410.
   PubMed Web of Science ®Google Scholar
• Leoni SG, Galante PA, Ricarte-Filho JC, Kimura ET. Differential gene expression analysis of iodide-treated rat thyroid follicular cell line PCCl3. Genomics 2008; 91: 356–366.
   PubMed Web of Science ®Google Scholar
• Uyttersprot N, Pelgrims N, Carrasco N, Gervy C, Maenhaut C, Dumont JE, Miot F. Moderate doses of iodide in vivo inhibit cell proliferation and the expression of thyroperoxidase and Na+/I− symporter mRNAs in dog thyroid. Mol Cell Endocrinol 1997; 131: 195–203.
   PubMedGoogle Scholar
• Eng PH, Cardona GR, Previti MC, Chin WW, Braverman LE. Regulation of the sodium iodide symporter by iodide in FRTL-5 cells. Eur J Endocrinol 2001; 144: 139–144.
   Google Scholar
• Yamazaki K, Mitsuhashi T, Yamada E, Yamada T, Kosaka S, Takano K, Obara T, Sato K. Amiodarone reversibly decreases sodium-iodide symporter mRNA expression at therapeutic concentrations and induces antioxidant responses at supraphysiological concentrations in cultured human thyroid follicles. Thyroid 2007; 17: 1189–1200.
   Google Scholar
• Postgard P, Himmelman J, Lindencrona U, Bhogal N, Wiberg D, Berg G, Jansson S, Nystrom E, Forssell-Aronsson E, Nilsson M. Stunning of iodide transport by 131I irradiation in cultured thyroid epithelial cells. J Nucl Med 2002; 43: 828–834.
   PubMed Web of Science ®Google Scholar
• Lundh C, Norden MM, Nilsson M, Forssell-Aronsson E. Reduced iodide transport (stunning) and DNA synthesis in thyrocytes exposed to low absorbed doses from 131I in vitro. J Nucl Med 2007; 48: 481–486.
   Google Scholar
• Meller B, Gaspar E, Deisting W, Czarnocka B, Baehre M, Wenzel BE. Decreased radioiodine uptake of FRTL-5 cells after 131I incubation in vitro: molecular biological investigations indicate a cell cycle-dependent pathway. Eur J Nucl Med Mol Imaging 2008; 35: 1204–1212.
   Google Scholar
• Schroder-van der Elst JP, van der Heide D, Kastelijn J, Rousset B, Obregon MJ. The expression of the sodium/iodide symporter is up-regulated in the thyroid of fetuses of iodine-deficient rats. Endocrinology 2001; 142: 3736–3741.
   Google Scholar
• Li H, Richard K, McKinnon B, Mortimer RH. Effect of iodide on human choriogonadotropin, sodium-iodide symporter expression, and iodide uptake in BeWo choriocarcinoma cells. J Clin Endocrinol Metab 2007; 92: 4046–4051.
   Google Scholar
• Everett LA, Glaser B, Beck JC, Idol JR, Buchs A, Heyman M, Adawi F, Hazani E, Nassir E, Baxevanis AD, Sheffield VC, Green ED. Pendred syndrome is caused by mutations in a putative sulphate transporter gene (PDS). Nat Genet 1997; 17: 411–422.
   PubMed Web of Science ®Google Scholar
• Kopp P, Pesce L, Solis SJ. Pendred syndrome and iodide transport in the thyroid. Trends Endocrinol Metab 2008; 19: 260–268.
   PubMed Web of Science ®Google Scholar
• Royaux IE, Suzuki K, Mori A, Katoh R, Everett LA, Kohn LD, Green ED. Pendrin, the protein encoded by the Pendred syndrome gene (PDS), is an apical porter of iodide in the thyroid and is regulated by thyroglobulin in FRTL-5 cells. Endocrinology 2000; 141: 839–845.
   PubMed Web of Science ®Google Scholar
• Bidart JM, Mian C, Lazar V, Russo D, Filetti S, Caillou B, Schlumberger M. Expression of pendrin and the Pendred syndrome (PDS) gene in human thyroid tissues. J Clin Endocrinol Metab 2000; 85: 2028–2033.
   PubMedGoogle Scholar
• Yoshida A, Taniguchi S, Hisatome I, Royaux IE, Green ED, Kohn LD, Suzuki K. Pendrin is an iodide-specific apical porter responsible for iodide efflux from thyroid cells. J Clin Endocrinol Metab 2002; 87: 3356–3361.
   PubMed Web of Science ®Google Scholar
• Gopal E, Fei YJ, Sugawara M, Miyauchi S, Zhuang L, Martin P, Smith SB, Prasad PD, Ganapathy V. Expression of slc5a8 in kidney and its role in Na+-coupled transport of lactate. J Biol Chem 2004; 279: 44522–44532.
   PubMed Web of Science ®Google Scholar
• Gopal E, Miyauchi S, Martin PM, Ananth S, Roon P, Smith SB, Ganapathy V. Transport of nicotinate and structurally related compounds by human SMCT1 (SLC5A8) and its relevance to drug transport in the mammalian intestinal tract. Pharm Res 2007; 24: 575–584.
   PubMed Web of Science ®Google Scholar
• Li H, Myeroff L, Smiraglia D, Romero MF, Pretlow TP, Kasturi L, Lutterbaugh J, Rerko RM, Casey G, Issa JP, Willis J, Willson JK, Plass C, Markowitz SD. SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci USA 2003; 100: 8412–8417.
   PubMed Web of Science ®Google Scholar
• Ganapathy V, Gopal E, Miyauchi S, Prasad PD. Biological functions of SLC5A8, a candidate tumour suppressor. Biochem Soc Trans 2005; 33: 237–240.
   Google Scholar
• Thangaraju M, Gopal E, Martin PM, Ananth S, Smith SB, Prasad PD, Sterneck E, Ganapathy V. SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases. Cancer Res 2006; 66: 11560–11564.
   PubMedGoogle Scholar
• Mian C, Lacroix L, Bidart JM, Caillou B, Filetti S, Schlumberger M. Sodium/iodide symporter in thyroid cancer. Exp Clin Endocrinol Diabetes 2001; 109: 47–51.
   Google Scholar
• Arturi F, Russo D, Bidart JM, Scarpelli D, Schlumberger M, Filetti S. Expression pattern of the pendrin and sodium/iodide symporter genes in human thyroid carcinoma cell lines and human thyroid tumors. Eur J Endocrinol 2001; 145: 129–135.
   PubMedGoogle Scholar
• Kondo T, Nakamura N, Suzuki K, Murata S, Muramatsu A, Kawaoi A, Katoh R. Expression of human pendrin in diseased thyroids. J Histochem Cytochem 2003; 51: 167–173.
   Google Scholar
• Skubis-Zegadlo J, Nikodemska A, Przytula E, Mikula M, Bardadin K, Ostrowski J, Wenzel BE, Czarnocka B. Expression of pendrin in benign and malignant human thyroid tissues. Br J Cancer 2005; 93: 144–151.
   PubMed Web of Science ®Google Scholar
• Gillam MP, Sidhaye AR, Lee EJ, Rutishauser J, Stephan CW, Kopp P. Functional characterization of pendrin in a polarized cell system. Evidence for pendrin-mediated apical iodide efflux. J Biol Chem 2004; 279: 13004–13010.
   PubMed Web of Science ®Google Scholar
• Porra V, Bernier-Valentin F, Trouttet-Masson S, Berger-Dutrieux N, Peix JL, Perrin A, Selmi-Ruby S, Rousset B. Characterization and semiquantitative analyses of pendrin expressed in normal and tumoral human thyroid tissues. J Clin Endocrinol Metab 2002; 87: 1700–1707.
   PubMed Web of Science ®Google Scholar
• Lacroix L, Pourcher T, Magnon C, Bellon N, Talbot M, Intaraphairot T, Caillou B, Schlumberger M, Bidart JM. Expression of the apical iodide transporter in human thyroid tissues: a comparison study with other iodide transporters. J Clin Endocrinol Metab 2004; 89: 1423–1428.
   PubMedGoogle Scholar
• Porra V, Ferraro-Peyret C, Durand C, Selmi-Ruby S, Giroud H, Berger-Dutrieux N, Decaussin M, Peix JL, Bournaud C, Orgiazzi J, Borson-Chazot F, Dante R, Rousset B. Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. J Clin Endocrinol Metab 2005; 90: 3028–3035.
   PubMedGoogle Scholar
• Suzuki K, Kohn LD. Differential regulation of apical and basal iodide transporters in the thyroid by thyroglobulin. J Endocrinol 2006; 189: 247–255.
   Google Scholar